NetworkNewsBreaks – Cardiome Pharma Corp. (NASDAQ: CRME) Initiates Commercial Launch of Xydalba™ in Three European Countries
Cardiome Pharma (NASDAQ: CRME) (TSX: COM) has initiated the commercial launch of Xydalba™ in Sweden, Finland and the Republic of Ireland, per the company’s announcement this morning. The European Medicines Agency (EMA) has approved Xydalba for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) in adults. Xydalba was approved by the U.S. Food and Drug Administration (FDA) in 2014 for the treatment of adult patients with ABSSSI caused by susceptible Gram-positive bacteria, including MRSA. "Our geographic footprint continues to expand, allowing us to make our portfolio of differentiated hospital products available to patients through our ex-U.S. global…







